


Envisia[®]
GENOMIC CLASSIFIER

Have you been told
you may have
pulmonary
fibrosis?




The Envisia Classifier
can help your doctor
diagnose your condition
with confidence and
decide on the best
course of treatment for
you with fewer delays.

What is the Envisia[®] Genomic Classifier and how can it help?

The Envisia test looks
at the genes of the
tissue in your lungs

without
surgery



Accurate in 9 out of 10 patients
with a positive result[†]

The test detects a pattern called UIP (usual interstitial pneumonia) that is associated with forms of scarring in your lungs. This pattern may be seen with IPF (idiopathic pulmonary fibrosis) or other types of interstitial lung disease.

The Envisia test result can help your doctor make a more confident diagnosis and treatment plan. Talk to your doctor about whether or not Envisia testing is right for you.

[†]Richeldi L, et al. *American Journal of Respiratory and Critical Care Medicine*, July 2020.

The importance of accurately diagnosing pulmonary fibrosis



The earlier and more accurate your diagnosis is, the more likely you are to slow the disease process and to improve your quality of life.*


Your doctor is considering the Envisia® test for you because you may have scarring on your lungs, known as **pulmonary fibrosis**. There are many types of lung disease that can cause scarring.

The Envisia test, in combination with other diagnostic information, can help your doctor **determine what type of pulmonary fibrosis you have to best inform your treatment** and the likely course of disease.



Before ordering an Envisia test for you, your doctor may:

- Review your medical history
- Perform a physical exam
- Order or review a CT scan of your chest
- Run blood tests
- Conduct a lung function test to measure your breathing capacity



How does the Envisia Genomic Classifier work?

For the Envisia test, your doctor will perform a **non-surgical procedure called a bronchoscopy** to collect a small sample of lung tissue.



A doctor collects 3-5 lung tissue samples during a bronchoscopy and sends them to the lab for Envisia testing



The test looks at 190 genes commonly associated with fibrosis or inflammation



The results indicate either positive or negative for UIP, which helps guide next steps; results are available within 2 weeks

During a bronchoscopy, a doctor will use a thin, flexible tube that goes into your lungs to collect small tissue samples. This procedure is usually done in an outpatient clinic or in a hospital. The entire procedure, including prep and recovery time, may take a few hours while the bronchoscopy itself usually lasts **20–30 minutes**.

Your doctor will talk to you about the risks and benefits of this procedure.

*Cosgrove GP, Bianchi P, Danese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018

Support and resources for accessing the Envisia test



Veracyte is committed to providing eligible patients with access to our test, regardless of your financial situation.



For Medicare patients, there is no copay (this does not apply to all Medicare Advantage plans)



For privately insured patients, copay is determined by your individual plan design



The Veracyte Access Program provides financial support for patients with financial need

To learn more and to find institutions that offer Envisia testing, visit envisiatest.com



If you have questions regarding getting Envisia testing or the Veracyte Access Program, please contact us and we'll be happy to help.

 (844) 464-LUNG

 support@veracyte.com

Providing answers and more confident treatment choices

The Envisia Genomic Classifier is the first genomic test that can help improve doctors' ability to differentiate pulmonary fibrosis from other forms of interstitial lung disease (ILD).

The Envisia Genomic Classifier:

- ✔ has been available **since 2019**
- ✔ has been used at **over 400 centers** in the US[†]
- ✔ has helped **over 4,000 patients** get on the best possible treatment path[†]



“As an IPF patient, the Envisia genomic test ended my 18-month diagnostic odyssey of uncertainty. I got a definitive diagnosis and prognosis that we could begin to plan around.”

—Keith Boyle, Rare Disease Awareness Ambassador & Patient Advocate

[Hear more about Keith's story](#)

Individual results may vary.

[†]Veracyte data on file as of August 2022.

FC3211.2209 © 2022 Veracyte, Inc. All rights reserved. The Veracyte and Envisia names and logos are trademarks of Veracyte, Inc. The Envisia Sequencing Classifier test is available as part of Veracyte's CLIA-validated laboratory-developed test (LDT) service. This test has not been cleared or approved by the FDA.